Efinaconazole - Valeant Pharmaceuticals International

Drug Profile

Efinaconazole - Valeant Pharmaceuticals International

Alternative Names: Clenafin; IDP-108; Jublia; KP-103

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaken Pharmaceutical
  • Developer Dong-A ST; Kaken Pharmaceutical; Valeant Pharmaceuticals International
  • Class Antifungals; Piperidines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis

Most Recent Events

  • 13 Nov 2017 USPTO grants petition for inter partes review filed by Argentum Pharmaceuticals against Valeant Pharmaceuticals for patent claims covering efinaconazole topical solution 10% in USA
  • 08 Nov 2017 Efinaconazole market licensed to Tai Tien Pharmaceuticals in Taiwan
  • 08 Nov 2017 Tai Tien Pharmaceuticals intends to launch Efinaconazole in Taiwan in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top